Phase II Clinical Trial of Pasireotide LAR in Patients with Metastatic Neuroendocrine Tumors

#792

Introduction: Pasireotide LAR is a novel SSA with avid binding to SSTR 1, 2, 3 and 5. It has never been investigated in treatment naïve patients.

Aim(s): To evaluate the antiproliferative efficacy and tolerability of Pasireotide LAR as a first-line agent in low-intermediate grade NETs.

Materials and methods: We performed a phase II trial of first-line pasireotide LAR 60mg in patients with metastatic G1-G2 NETs. Prior systemic therapy, including octreotide and lanreotide, was not permitted. The primary endpoint was PFS. SSTR subtype analysis was performed on archival tissue.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Strosberg J

Authors: Cives M, Kunz P, Nguyen P, Jump H, Vilay K,

Keywords: NET, pasireotide, first-line,